About Us
TREVENTIS™ Corporation is dedicated to treating and preventing protein misfolding diseases. We utilize a proprietary, patented discovery engine – Common Conformational Morphology (CCM) – to identify druggable active sites in misfolded protein targets. CCM combines unique in silico models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets. Our Takeda-partnered lead program focuses on anti-misfolding small molecules in Alzheimer’s disease. We have further CCM-driven, U.S. DOD-funded efforts in oncology and other neurodegenerative diseases that show the wide utility of our technology platform.
Management

Christopher J. Barden
Chief Executive Officer

Donald F. Weaver
Chief Medical Officer

Mark Reed
Chief Scientific Officer

Marcia Taylor
SVP Research

Seung-Pil Yang
Biology Group Leader

Carlos Zepeda
Chemistry Group Leader
Board of Directors

Gregory Harriman, M.D.
Independent Director

Maria Maccecchini, Ph.D.
Independent Director

L. William McIntosh, B.S., M.B.A.
Chairman and Founder

Timothy J. Williamson, B.A.
Independent Director

William Wong, Ph.D.
Founder